Literature DB >> 18483278

Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis.

Nabiha Yusuf1, Tahseen H Nasti, Santosh K Katiyar, Michael K Jacobs, Megan D Seibert, Alexis C Ginsburg, Laura Timares, Hui Xu, Craig A Elmets.   

Abstract

The role that cell-mediated immune responses play during cutaneous carcinogenesis has received little attention. In this study, we evaluated the contribution of CD4(+) and CD8(+) T cells in C3H/HeN mice that were subjected to a two-stage 7,12-dimethylbenz(a)anthracene (DMBA) initiation, 12-O-tetradecanoylphorbol-13-acetate (TPA) promotion skin carcinogenesis protocol. In CD8 knockout (CD8(-/-)) mice, allergic contact hypersensitivity to DMBA was reduced compared with wild-type (WT) C3H/HeN mice. On the other hand, CD4 knockout (CD4(-/-)) mice developed an exaggerated contact hypersensitivity response. CD4(+) T cells from DMBA contact-sensitized mice preferentially produced interleukin 4 (IL-4), IL-10, and IL-17; CD8(+) T cells, on the other hand, secreted IFN-gamma. When CD4(-/-), CD8(-/-), and WT mice were subjected to a standard two-stage DMBA/TPA cutaneous carcinogenesis protocol, the percentage of mice with tumors was much greater (P < 0.001) in CD8(-/-) mice than in WT mice. In contrast, the percentage of tumors was significantly less (P < 0.001) in CD4(-/-) mice than in WT mice. Similar results were obtained when the data were evaluated as the number of tumors per mouse. These findings indicate that (a) CD8(+) T cells are the predominant effector cells in allergic contact hypersensitivity to DMBA and that CD4(+) T cells have an inhibitory role and (b) the development of CD8(+) T cells plays a protective role in skin tumor development whereas CD4(+) T cells have the opposite effect. Manipulation of T-cell subpopulations that are induced by carcinogenic chemicals, like DMBA, could be a means of preventing skin cancers caused by these agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483278      PMCID: PMC3769418          DOI: 10.1158/0008-5472.CAN-07-3059

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Interleukin-17 promotes angiogenesis and tumor growth.

Authors:  Muneo Numasaki; Jun-ichi Fukushi; Mayumi Ono; Satwant K Narula; Paul J Zavodny; Toshio Kudo; Paul D Robbins; Hideaki Tahara; Michael T Lotze
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

2.  Elevated expression and point mutation of the Ha-ras proto-oncogene in mouse skin tumors promoted by benzoyl peroxide and other promoting agents.

Authors:  J C Pelling; S M Fischer; R Neades; J Strawhecker; L Schweickert
Journal:  Carcinogenesis       Date:  1987-10       Impact factor: 4.944

3.  Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.

Authors:  M Quintanilla; K Brown; M Ramsden; A Balmain
Journal:  Nature       Date:  1986 Jul 3-9       Impact factor: 49.962

4.  Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons.

Authors:  D Bizub; A W Wood; A M Skalka
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.

Authors:  Fabrice Benchetrit; Arnaud Ciree; Virginie Vives; Guy Warnier; Alain Gey; Catherine Sautès-Fridman; François Fossiez; Nacilla Haicheur; Wolf H Fridman; Eric Tartour
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

Review 6.  Interleukin-17 family members and inflammation.

Authors:  Jay K Kolls; Anders Lindén
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

7.  IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis.

Authors:  M C Honorati; S Neri; L Cattini; A Facchini
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 8.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 9.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer.

Authors:  Michael Girardi; Earl Glusac; Renata B Filler; Scott J Roberts; Iva Propperova; Julia Lewis; Robert E Tigelaar; Adrian C Hayday
Journal:  J Exp Med       Date:  2003-09-01       Impact factor: 14.307

View more
  29 in total

1.  In Vivo Suppression of Heat Shock Protein (HSP)27 and HSP70 Accelerates DMBA-Induced Skin Carcinogenesis by Inducing Antigenic Unresponsiveness to the Initiating Carcinogenic Chemical.

Authors:  Nabiha Yusuf; Tahseen H Nasti; Israr Ahmad; Sanim Chowdhury; Hasan Mohiuddin; Hui Xu; Mohammad Athar; Laura Timares; Craig A Elmets
Journal:  J Immunol       Date:  2015-04-03       Impact factor: 5.422

2.  T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis.

Authors:  Christophe Cataisson; Rosalba Salcedo; Aleksandra M Michalowski; Mary Klosterman; Shruti Naik; Luowei Li; Michelle J Pan; Amalia Sweet; Jin-Qiu Chen; Laurie G Kostecka; Megan Karwan; Loretta Smith; Ren-Ming Dai; C Andrew Stewart; Lyudmila Lyakh; Wang-Ting Hsieh; Asra Khan; Howard Yang; Maxwell Lee; Giorgio Trinchieri; Stuart H Yuspa
Journal:  Mol Cancer Res       Date:  2019-06-04       Impact factor: 5.852

3.  CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis.

Authors:  Ashley E Winkler; Joshua J Brotman; Meredith E Pittman; Nancy P Judd; James S Lewis; Robert D Schreiber; Ravindra Uppaluri
Journal:  Cancer Res       Date:  2011-07-06       Impact factor: 12.701

Review 4.  T cells in tumor microenvironment.

Authors:  Yağmur Kiraz; Yusuf Baran; Ayten Nalbant
Journal:  Tumour Biol       Date:  2015-10-18

5.  IL-23 Inhibits Melanoma Development by Augmenting DNA Repair and Modulating T Cell Subpopulations.

Authors:  Tahseen H Nasti; J Barry Cochran; Raj V Vachhani; Kristopher McKay; Yuko Tsuruta; Mohammad Athar; Laura Timares; Craig A Elmets
Journal:  J Immunol       Date:  2016-12-21       Impact factor: 5.422

6.  IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.

Authors:  Donggou He; Hui Li; Nabiha Yusuf; Craig A Elmets; Jun Li; John D Mountz; Hui Xu
Journal:  J Immunol       Date:  2010-01-29       Impact factor: 5.422

7.  Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice.

Authors:  Mohammed Naseemuddin; Aneeqa Iqbal; Tahseen H Nasti; Jennifer L Ghandhi; Akash D Kapadia; Nabiha Yusuf
Journal:  Int J Cancer       Date:  2011-06-18       Impact factor: 7.396

8.  Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis.

Authors:  Nabiha Yusuf; Tahseen H Nasti; Sreelatha Meleth; Craig A Elmets
Journal:  Mol Carcinog       Date:  2009-08       Impact factor: 4.784

9.  Targeted deletion of RasGRP1 impairs skin tumorigenesis.

Authors:  Amrish Sharma; Lauren L Fonseca; Cynthia Rajani; Jodi K Yanagida; Yuka Endo; J Mark Cline; James C Stone; Junfang Ji; Joe W Ramos; Patricia S Lorenzo
Journal:  Carcinogenesis       Date:  2014-01-24       Impact factor: 4.944

10.  Silymarin inhibits ultraviolet radiation-induced immune suppression through DNA repair-dependent activation of dendritic cells and stimulation of effector T cells.

Authors:  Mudit Vaid; Ram Prasad; Tripti Singh; Craig A Elmets; Hui Xu; Santosh K Katiyar
Journal:  Biochem Pharmacol       Date:  2013-02-05       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.